Home LiteratureArticle Details
PMID: 12771128 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148.

The Journal of cell biology ·Vol. 161 ·No. 4 ·2003-05-26 ·Pages 793-804

Grazia Lampugnani M, Zanetti A, Corada M, Takahashi T, Balconi G, Breviario F, Orsenigo F, Cattelino A, Kemler R, Daniel TO, Dejana E

Abstract

Confluent endothelial cells respond poorly to the proliferative signals of VEGF. Comparing isogenic endothelial cells differing for vascular endothelial cadherin (VE-cadherin) expression only, we found that the presence of this protein attenuates VEGF-induced VEGF receptor (VEGFR) 2 phosphorylation in tyrosine, p44/p42 MAP kinase phosphorylation, and cell proliferation. VE-cadherin truncated in beta-catenin but not p120 binding domain is unable to associate with VEGFR-2 and to induce its inactivation. beta-Catenin-null endothelial cells are not contact inhibited by VE-cadherin and are still responsive to VEGF, indicating that this protein is required to restrain growth factor signaling. A dominant-negative mutant of high cell density-enhanced PTP 1 (DEP-1)//CD148 as well as reduction of its expression by RNA interference partially restore VEGFR-2 phosphorylation and MAP kinase activation. Overall the data indicate that VE-cadherin-beta-catenin complex participates in contact inhibition of VEGF signaling. Upon stimulation with VEGF, VEGFR-2 associates with the complex and concentrates at cell-cell contacts, where it may be inactivated by junctional phosphatases such as DEP-1. In sparse cells or in VE-cadherin-null cells, this phenomenon cannot occur and the receptor is fully activated by the growth factor.

MeSH Terms
Animals Antigens, CD Cadherins/genetics,metabolism Cell Division/drug effects Cell Line Cells, Cultured Contact Inhibition Cytoskeletal Proteins/metabolism Dose-Response Relationship, Drug Endothelial Growth Factors/pharmacology Endothelium, Vascular/cytology,drug effects Humans Intercellular Signaling Peptides and Proteins/pharmacology Lymphokines/pharmacology Mice Mitogen-Activated Protein Kinases/metabolism Phosphorylation Protein Binding Protein Tyrosine Phosphatases/metabolism Receptor-Like Protein Tyrosine Phosphatases, Class 3 Trans-Activators/metabolism Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor Receptor-2/metabolism Vascular Endothelial Growth Factors beta Catenin
Chemicals
Antigens, CD CTNNB1 protein, human CTNNB1 protein, mouse Cadherins Cytoskeletal Proteins Endothelial Growth Factors Intercellular Signaling Peptides and Proteins Lymphokines Trans-Activators Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors beta Catenin cadherin 5 Vascular Endothelial Growth Factor Receptor-2 Mitogen-Activated Protein Kinases PTPRJ protein, human Protein Tyrosine Phosphatases Ptprj protein, mouse Receptor-Like Protein Tyrosine Phosphatases, Class 3
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Grazia Lampugnani Maria
FIRC Institute of Molecular Oncology, 20139 Milan, Italy.
Zanetti Adriana
Corada Monica
Takahashi Takamune
Balconi Giovanna
Breviario Ferruccio
Orsenigo Fabrizio
Cattelino Anna
Kemler Rolf
Daniel Thomas O
Dejana Elisabetta
References (60)
60 references, click to expand
  1. Clinical applications of angiogenic growth factors and their inhibitors.
    Nat Med. 1999 Dec;5(12):1359-64 PMID: 10581076
  2. Cell confluence regulates tyrosine phosphorylation of adherens junction components in endothelial cells.
    J Cell Sci. 1997 Sep;110 ( Pt 17):2065-77 PMID: 9378757
  3. SHP2 association with VE-cadherin complexes in human endothelial cells is regulated by thrombin.
    J Biol Chem. 2000 Feb 25;275(8):5983-6 PMID: 10681592
  4. Development of endothelial cell lines from embryonic stem cells: A tool for studying genetically manipulated endothelial cells in vitro.
    Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1443-51 PMID: 10845856
  5. Wnt signaling and cancer.
    Genes Dev. 2000 Aug 1;14(15):1837-51 PMID: 10921899
  6. Angiogenesis in cancer and other diseases.
    Nature. 2000 Sep 14;407(6801):249-57 PMID: 11001068
  7. Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1).
    Mol Cell Biol. 2000 Dec;20(24):9236-46 PMID: 11094075
  8. Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation.
    J Biol Chem. 2000 Dec 29;275(52):41227-33 PMID: 10969083
  9. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo.
    Dev Biol. 2001 Feb 15;230(2):230-42 PMID: 11161575
  10. Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability.
    Blood. 2001 Mar 15;97(6):1679-84 PMID: 11238107
  11. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin.
    Cell. 2001 Feb 23;104(4):605-17 PMID: 11239416
  12. Combinatorial control of the specificity of protein tyrosine phosphatases.
    Curr Opin Cell Biol. 2001 Apr;13(2):182-95 PMID: 11248552
  13. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells.
    J Biol Chem. 1998 May 22;273(21):13313-6 PMID: 9582377
  14. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).
    J Cell Biol. 1998 Jul 27;142(2):557-71 PMID: 9679152
  15. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.
    Cancer Metastasis Rev. 1998 Jun;17(2):155-61 PMID: 9770111
  16. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.
    J Biol Chem. 1998 Nov 13;273(46):30336-43 PMID: 9804796
  17. p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry.
    Oncogene. 1999 Jan 28;18(4):869-76 PMID: 10023662
  18. Confluence of vascular endothelial cells induces cell cycle exit by inhibiting p42/p44 mitogen-activated protein kinase activity.
    Mol Cell Biol. 1999 Apr;19(4):2763-72 PMID: 10082542
  19. Interactions between mitogenic stimuli, or, a thousand and one connections.
    Curr Opin Cell Biol. 1999 Apr;11(2):197-202 PMID: 10209147
  20. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells.
    Oncogene. 1999 Apr 1;18(13):2221-30 PMID: 10327068
  21. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis.
    Cell. 1999 Jul 23;98(2):147-57 PMID: 10428027
  22. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo.
    Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9815-20 PMID: 10449777
  23. Molecular and biological properties of vascular endothelial growth factor.
    J Mol Med (Berl). 1999 Jul;77(7):527-43 PMID: 10494799
  24. Endothelial localization of receptor tyrosine phosphatase, ECRTP/DEP-1, in developing and mature renal vasculature.
    J Am Soc Nephrol. 1999 Oct;10(10):2135-45 PMID: 10505690
  25. A role for cadherin-5 in regulation of vascular endothelial growth factor receptor 2 activity in endothelial cells.
    Mol Biol Cell. 1999 Oct;10(10):3401-7 PMID: 10512875
  26. Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development.
    Development. 2001 Apr;128(8):1253-64 PMID: 11262227
  27. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation.
    J Biol Chem. 2001 May 25;276(21):17686-92 PMID: 11278468
  28. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner.
    J Cell Biol. 2001 May 28;153(5):1049-60 PMID: 11381089
  29. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.
    EMBO J. 2001 Jun 1;20(11):2768-78 PMID: 11387210
  30. E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity.
    J Cell Biol. 2001 Sep 17;154(6):1185-96 PMID: 11564756
  31. Adhesion signaling: how beta-catenin interacts with its partners.
    Curr Biol. 2001 Oct 2;11(19):R792-4 PMID: 11591340
  32. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation.
    J Biol Chem. 2001 Dec 28;276(52):49289-98 PMID: 11682481
  33. Vascular endothelial growth factor induces SHC association with vascular endothelial cadherin: a potential feedback mechanism to control vascular endothelial growth factor receptor-2 signaling.
    Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):617-22 PMID: 11950700
  34. VE-cadherin regulates endothelial actin activating Rac and increasing membrane association of Tiam.
    Mol Biol Cell. 2002 Apr;13(4):1175-89 PMID: 11950930
  35. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy.
    EMBO J. 2002 Apr 15;21(8):1939-47 PMID: 11953313
  36. The cadherin-catenin adhesion system in signaling and cancer.
    J Clin Invest. 2002 Apr;109(8):987-91 PMID: 11956233
  37. WNT signaling and lymphocyte development.
    Cell. 2002 Apr;109 Suppl:S13-9 PMID: 11983149
  38. VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells.
    Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9462-7 PMID: 12080144
  39. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability.
    Blood. 2002 Aug 1;100(3):905-11 PMID: 12130501
  40. beta-Catenin is not required for proliferation and differentiation of epidermal mouse keratinocytes.
    J Cell Sci. 2002 Dec 1;115(Pt 23):4587-95 PMID: 12415003
  41. Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1.
    J Biol Chem. 2003 Feb 21;278(8):5728-35 PMID: 12475979
  42. A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development.
    Mol Cell Biol. 2003 Mar;23(5):1817-31 PMID: 12588999
  43. Mechanisms of endothelial growth control.
    Am J Respir Cell Mol Biol. 1992 Jan;6(1):1-8 PMID: 1728288
  44. Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase Cgamma1 phosphorylation.
    Mol Cell Biol. 2001 Apr;21(7):2393-403 PMID: 11259588
  45. The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions.
    EMBO J. 1992 May;11(5):1733-42 PMID: 1316270
  46. A novel endothelial-specific membrane protein is a marker of cell-cell contacts.
    J Cell Biol. 1992 Sep;118(6):1511-22 PMID: 1522121
  47. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.
    Oncogene. 1994 Nov;9(11):3379-87 PMID: 7936666
  48. Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density.
    Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9680-4 PMID: 7937872
  49. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor.
    J Cell Biol. 1994 Dec;127(5):1375-80 PMID: 7962096
  50. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression.
    J Virol. 1995 Aug;69(8):4600-6 PMID: 7609024
  51. Receptor protein tyrosine phosphatase PTPmu associates with cadherins and catenins in vivo.
    J Cell Biol. 1995 Aug;130(4):977-86 PMID: 7642713
  52. Association of human protein-tyrosine phosphatase kappa with members of the armadillo family.
    J Biol Chem. 1996 Jul 12;271(28):16712-9 PMID: 8663237
  53. Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion.
    Exp Cell Res. 1996 Jul 10;226(1):214-22 PMID: 8660958
  54. Regulated binding of PTP1B-like phosphatase to N-cadherin: control of cadherin-mediated adhesion by dephosphorylation of beta-catenin.
    J Cell Biol. 1996 Aug;134(3):801-13 PMID: 8707857
  55. Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin).
    J Clin Invest. 1996 Aug 15;98(4):886-93 PMID: 8770858
  56. Association between a transmembrane protein tyrosine phosphatase and the cadherin-catenin complex.
    J Cell Biol. 1996 Sep;134(6):1519-29 PMID: 8830779
  57. Expression of the protein tyrosine phosphatase beta2 gene in mouse erythroleukemia cells induces terminal erythroid differentiation.
    J Biol Chem. 1996 Nov 29;271(48):30916-21 PMID: 8940077
  58. Cell contact-dependent signaling.
    Dev Biol. 1996 Dec 15;180(2):445-54 PMID: 8954717
  59. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts.
    Oncogene. 1997 May 1;14(17):2079-89 PMID: 9160888
  60. p21WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression.
    Cancer Res. 2000 Jan 1;60(1):156-63 PMID: 10646868
Article Info
Journal
The Journal of cell biology
Abbr.
J Cell Biol
ISSN
0021-9525
Published
2003-05-26
Pages
793-804
Language
English
Region
United States
NLM ID
0375356
PMCID
PMC2199373
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com